Key Quantitative Figures - Financial Results (H1 FY27 ended 30.09.2026)

  • Total Income: ₹1,681.32 Lakh
  • Revenue from Operations: ₹1,526.58 Lakh
  • Other Income: ₹154.73 Lakh
  • Total Expenses: ₹1,243.98 Lakh
  • Cost of materials consumed: ₹801.06 Lakh
  • Employee benefits expense: ₹140.52 Lakh
  • Finance Cost: ₹26.30 Lakh
  • Depreciation and Amortisation: ₹32.13 Lakh
  • Other Expenses: ₹243.96 Lakh
  • Profit Before Tax (PBT): ₹437.33 Lakh
  • Total Tax Expense: ₹109.96 Lakh
  • Current Tax: ₹100.03 Lakh
  • Deferred Tax: ₹9.93 Lakh
  • Net Profit for the Period: ₹327.37 Lakh
  • Paid-up Equity Share Capital: ₹1,092.28 Lakh (Face Value: ₹10/- per share)
  • Earnings Per Share (EPS): ₹3.70 (Basic and Diluted)

Key Quantitative Figures - Balance Sheet (as of 30.09.2026)

  • Total Equity: ₹6,985.17 Lakh
  • Equity Share Capital: ₹1,092.28 Lakh
  • Reserves and Surplus: ₹5,892.89 Lakh
  • Total Liabilities: ₹8,314.53 Lakh
  • Total Assets: ₹8,314.53 Lakh
  • Non-Current Assets: ₹1,096.96 Lakh
  • Current Assets: ₹7,217.58 Lakh
  • Inventories: ₹241.68 Lakh
  • Trade Receivables: ₹4,413.26 Lakh
  • Cash and Cash Equivalents: ₹1,598.63 Lakh
  • Short-term loans and advances: ₹964.01 Lakh

Key Quantitative Figures - Cash Flow (H1 FY27 ended 30.09.2026)

  • Net Cash from Operating Activities: (₹656.69) Lakh
  • Net Cash from Investing Activities: (₹620.93) Lakh
  • Purchase of property, plant & equipment: (₹26.97) Lakh
  • Purchase of Fixed Deposits: (₹594.00) Lakh
  • Net Cash from Financing Activities: ₹2,747.16 Lakh
  • Proceeds from Issue of Equity Share Capital (net): ₹2,771.58 Lakh
  • Net Increase in Cash: ₹1,469.54 Lakh

Dates of Action

  • Board Meeting Date: 12th November, 2026 (commenced at 4:00 PM, concluded at 4:20 PM)
  • Period of Financial Results: Half Year ended 30th September, 2026
  • Preferential Allotment Approval Dates: Board approval on 2nd July 2026; Shareholder approval at EGM on 31st July 2026.

Parties Involved

  • Statutory Auditors: Panchal SK & Associates (Firm Registration No.: 145989W)
  • Signatories: Rishi Upadhaya (Company Secretary and Compliance Officer), Ashish Sakalkar (Managing Director, DIN: 06601011)

Capital Structure Impact

Pursuant to approvals from the Board of Directors (2nd July 2026) and shareholders at an Extraordinary General Meeting (31st July 2026), the Company allotted 24,10,431 equity shares of face value ₹10/- each on a preferential basis. This increased the paid-up equity share capital from ₹851.24 Lakh (as of 31.03.2026) to ₹1,092.28 Lakh (as of 30.09.2026). The newly allotted shares rank pari passu with existing equity shares.

Notes to Financial Results

  • The financial results were reviewed by the Audit Committee and approved by the Board of Directors.
  • The Statutory Auditors have carried out a limited review of these results.
  • The company has only one reportable segment: Pharmaceuticals business.
  • Figures for the previous period (half year ended 31.03.2026) are balancing figures between the audited annual figures and the previous unaudited half-yearly figures.